AquaCelle® bioavailability

Supercharge Bioavailability

Micellar Technology

Award winning, AquaCelle® is a customisable, self micro-emulsifying delivery system (SMEDS). Specifically designed and clinically proven to optimise the bioavailability of oily lipophilic active ingredients such as, ubiquinol, omega-3s, lutein and resveratrol whilst maintaining product stability.

Clinically shown to improve bioavailability by up to 700%.

Optimised for Functionality

Combine supercharged bioavailability with format functionality, an AquaCelle® enhanced oily active ingredient can easily be transformed into a solid free flowing powder when loaded onto CPO® technology.

AquaCelle® logo
CPO®  logo

AquaCelle® Advantages:

  • optimised biovailablity

  • increased functionality

  • innovative dosage formats

  • reduced dose size

  • highly customisable

  • clinically validated with human pharmacokinetic studies

  • improved stability, overcomes associated risks and overages

  • reduces unwanted reflux from omega-3 actives

  • polysorbate free

  • the use of pharmacopoeial grade ingredients

  • patented technology

  • Australian developed and made

AquaCelle® micelle cross section

Published Studies

AquaCelle® CoQ10 PK graph

AquaCelle® CoQ10 impacts on micelle size & increases ubiquinone absorption

The novel delivery system AquaCelle® demonstrated superior supply of ubiquinone (Q10) when compared with a standard ubiquinone extract.

AquaCelle® Fish Oil PK  study image

AquaCelle® Omega-3 improves EPA and DHA bioavailability

The study assessed the ability of a self-emulsifying drug delivery system (SEDDS), AquaCelle®, as an additive to enhance the oral absorption of Omega-3 ethyl esters (EE) in healthy subjects under low-fat diet conditions.

Awards and Grants

Dept of Industry NSW logo

NSW Department of Industry Tech Connections voucher granted for AquaCelle® Omega Study

NutraIngredients USA  2020  winner logo

Ingredient of the Year Healthy Ageing AquaCelle® Q10

AquaCelle® is a patented technology, and a trademark owned exclusively by Pharmako Biotechnologies Pty. Ltd., registered in Australia and other countries.